[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20024528L - Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen - Google Patents

Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen

Info

Publication number
NO20024528L
NO20024528L NO20024528A NO20024528A NO20024528L NO 20024528 L NO20024528 L NO 20024528L NO 20024528 A NO20024528 A NO 20024528A NO 20024528 A NO20024528 A NO 20024528A NO 20024528 L NO20024528 L NO 20024528L
Authority
NO
Norway
Prior art keywords
compound
pharmaceutical composition
protease inhibitor
protease
inhibitor
Prior art date
Application number
NO20024528A
Other languages
English (en)
Other versions
NO20024528D0 (no
Inventor
Daniel Frank Veber
Dennis Shinji Yamashita
Jr Robert Wells Marquis
Maxwell David Cummings
Yu Ru
Scott Kevin Thompson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20024528D0 publication Critical patent/NO20024528D0/no
Publication of NO20024528L publication Critical patent/NO20024528L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024528A 2000-03-21 2002-09-20 Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen NO20024528L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19100000P 2000-03-21 2000-03-21
US20634100P 2000-05-23 2000-05-23
US21175900P 2000-06-14 2000-06-14
US21744500P 2000-07-10 2000-07-10
PCT/US2001/007094 WO2001070232A1 (en) 2000-03-21 2001-03-07 Protease inhibitors

Publications (2)

Publication Number Publication Date
NO20024528D0 NO20024528D0 (no) 2002-09-20
NO20024528L true NO20024528L (no) 2002-11-19

Family

ID=27497873

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024528A NO20024528L (no) 2000-03-21 2002-09-20 Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen

Country Status (26)

Country Link
US (2) US7071184B2 (no)
EP (1) EP1307203A4 (no)
JP (1) JP2003527429A (no)
KR (1) KR20020082896A (no)
CN (1) CN1416346A (no)
AP (1) AP1540A (no)
AR (1) AR032877A1 (no)
AU (2) AU2001243441B2 (no)
BG (1) BG106962A (no)
BR (1) BR0109356A (no)
CA (1) CA2404206A1 (no)
CZ (1) CZ20023168A3 (no)
DZ (1) DZ3318A1 (no)
EA (1) EA005893B1 (no)
HU (1) HUP0300068A2 (no)
IL (1) IL150964A0 (no)
MX (1) MXPA02009305A (no)
MY (1) MY141596A (no)
NO (1) NO20024528L (no)
NZ (1) NZ520588A (no)
OA (1) OA12323A (no)
PE (1) PE20011233A1 (no)
PL (1) PL357727A1 (no)
SK (1) SK13632002A3 (no)
UY (1) UY26625A1 (no)
WO (1) WO2001070232A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128476A1 (en) * 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
MXPA02009305A (es) 2000-03-21 2003-03-12 Smithkline Beecham Corp Inhibidores de proteasa.
CO5280088A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
CO5280093A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Metodos de tratamiento
EP1320370A4 (en) * 2000-09-01 2008-10-22 Smithkline Beecham Corp TREATMENT METHOD
JP2005513083A (ja) * 2000-11-22 2005-05-12 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
AU2002360409A1 (en) * 2001-11-21 2003-06-10 Smithkline Beecham Corporation Methods and intermediates for the synthesis of azepines
WO2003097593A2 (en) * 2002-05-22 2003-11-27 Smithkline Beecham Corporation Protease inhibitors
CA2500317A1 (en) * 2002-10-08 2004-04-22 Merck Frosst Canada & Co. 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
US20040192674A1 (en) * 2003-02-14 2004-09-30 Marquis Robert W. Cathepsin L inhibitors
US20080262224A1 (en) * 2004-01-23 2008-10-23 Smithkline Beecham Corporation Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide
KR100603014B1 (ko) * 2004-07-21 2006-07-24 황호연 라벨용 포장필름의 제조방법, 상기 제조방법으로 제조된라벨용 포장필름 및 상기 포장필름의 사용방법
WO2006042150A1 (en) * 2004-10-07 2006-04-20 Vitae Pharmaceuticals, Inc. Diaminoalkane aspartic protease inhibitors
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
TWI411607B (zh) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2008149971A1 (ja) 2007-06-08 2008-12-11 Kyoto University 脳動脈瘤の治療または予防薬
US20100317697A1 (en) * 2007-06-20 2010-12-16 Baldwin John J Renin Inhibitors
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
EP2216047A4 (en) 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
MX2010014146A (es) * 2008-06-20 2011-01-21 Vitae Pharmaceuticals Inc Inhibidores de renina y metodo de uso de los mismos.
BRPI0915398A2 (pt) * 2008-06-26 2018-05-22 Vitae Pharmaceuticals Inc Composto de sais de metil 2-((r)-(3-clorofenil)((r)-2- (metilamino)3((r)-tetraidro-2h-piran-3-il) propilcarbamoil)piperidina-3-il)metoxi) etilcarbamato, composição famacêutica que o compreende, método de atagonização de uma ou mais proteases aspárticas em um paciente e para tratar um distúrbio mediano por protease aspártica
AR077692A1 (es) * 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
KR20140034821A (ko) 2011-05-16 2014-03-20 바이엘 인텔렉쳐 프로퍼티 게엠베하 폐고혈압 및/또는 심부전의 치료 및/또는 예방을 위한 카텝신 k 억제의 용도
CN103275070A (zh) * 2013-05-10 2013-09-04 郑彪 调节单核细胞增殖的四环化合物及其应用
WO2014199644A1 (ja) * 2013-06-14 2014-12-18 生化学工業株式会社 α－オキソアシルアミノカプロラクタム誘導体
EP3009425B1 (en) * 2013-06-14 2018-06-06 Seikagaku Corporation Alpha-oxoacylaminocaprolactam
AU2017326466B2 (en) 2016-09-16 2021-11-11 Lighthouse Pharmaceuticals, Inc. Ketone inhibitors of lysine gingipain
BR112022019245A2 (pt) * 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038247A (en) 1970-05-19 1977-07-26 Ciba-Geigy Corporation Stabilizing polyolefins with diacyl dihydrazides
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
IT1195287B (it) 1981-11-05 1988-10-12 Ausonia Farma Srl Derivato tiazolico,procedimento per la sua preparazione e relative composizioni farmaceutiche
US4518528A (en) 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US4749792A (en) 1984-09-26 1988-06-07 E. R. Squibb & Sons, Inc. Diamino ketones and alcohols as analgesic agents
US4638101A (en) 1985-01-02 1987-01-20 General Electric Company Compositions
US4638010A (en) * 1985-02-28 1987-01-20 E. R. Squibb & Sons, Inc. Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
JP2570686B2 (ja) 1985-12-23 1997-01-08 日産化学工業株式会社 ピラゾ−ル誘導体
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
EP0237082B1 (en) 1986-03-14 1991-05-29 Syntex (U.S.A.) Inc. 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
US5374637A (en) 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4994471A (en) 1989-05-12 1991-02-19 Boc, Inc. N-aryl-N-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
EP0504938A3 (en) 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
JPH05140063A (ja) 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
US5206251A (en) 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5216168A (en) 1992-04-01 1993-06-01 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
WO1994000095A2 (en) 1992-06-24 1994-01-06 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
EP0603769B1 (en) 1992-12-25 1998-09-16 Mitsubishi Chemical Corporation Alpha-Aminoketone derivatives
CA2111930A1 (en) 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
JPH06199850A (ja) 1992-12-28 1994-07-19 Tanabe Seiyaku Co Ltd インドール含有ペプチド及びその製法
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
CA2159080A1 (en) 1993-04-06 1994-10-13 Philip Stashenko Human osteoclast-specific and -related genes
CA2122227A1 (en) 1993-04-29 1994-10-30 Roland E. Dolle Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
AU7714594A (en) 1993-08-13 1995-03-14 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1beta converting enzyme
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
US5668128A (en) 1994-04-13 1997-09-16 Takeda Chemical Industries, Ltd. Aziridine derivatives, their production and use
US5585387A (en) 1994-10-07 1996-12-17 Torcan Chemical Ltd. Prepration of cisapride
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US5734977A (en) * 1994-11-10 1998-03-31 Telefonaktiebolaget Lm Ericsson Fraud detection in radio communications network
TW438591B (en) 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
HUP9802488A3 (en) 1995-10-30 2001-10-29 Smithkline Beecham Corp Method of inhibiting cathepsin k
AU1118097A (en) 1995-10-30 1997-05-22 Smithkline Beecham Corporation Protease inhibitors
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
US5902882A (en) 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
WO1997049668A1 (en) 1996-06-13 1997-12-31 Smithkline Beecham Corporation Inhibitiors of cysteine protease
WO1997047642A1 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Cathepsin k gene
US5861298A (en) 1996-06-17 1999-01-19 Smithkline Beecham Corporation Cathepsin K gene
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
US5830850A (en) 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
JP2000517319A (ja) 1996-08-28 2000-12-26 スミスクライン・ビーチャム・コーポレイション システインプロテアーゼのインヒビター
HUP9904165A3 (en) 1996-09-19 2002-01-28 Aventis Pharmaceuticals Inc Br 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
US5948669A (en) 1997-02-26 1999-09-07 Smithkline Beecham Corporation Rat cathepsin K polynucleotide and polypeptide sequence
AR012374A1 (es) 1997-04-15 2000-10-18 Smithkline Beecham Corp Inhibidores de proteasas, composiones farmaceuticas y usos para la preparacion de medicamentos.
WO1998049152A1 (en) 1997-04-25 1998-11-05 Smithkline Beecham Corporation Protease inhibitors
MA26487A1 (fr) 1997-04-29 2004-12-20 Smithkline Beecham Corp Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .
US6566373B2 (en) 1997-05-06 2003-05-20 Smithkline Beecham Corporation Protease inhibitors
HUP0001285A3 (en) 1997-05-08 2000-10-30 Smithkline Beecham Corp Philap Pyrrolidine derivatives as protease inhibitors, process for producing them and pharmaceutical compositions containing them
KR20010012325A (ko) 1997-05-08 2001-02-15 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제
MA26540A1 (fr) 1997-09-04 2004-12-20 Smithkline Beecham Corp Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant.
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
DZ2796A1 (fr) 1998-05-21 2003-12-01 Smithkline Beecham Corp Composés à fonction bis-aminométhyl-carbonyle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CA2332492A1 (en) 1998-05-21 1999-11-25 Stacie Marie Halbert Protease inhibitors
DZ2815A1 (fr) 1998-06-12 2003-12-01 Smithkline Beecham Corp Inhibiteurs de protéase.
AR018915A1 (es) 1998-06-24 2001-12-12 Smithkline Beecham Corp Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
JP2003527819A (ja) 1998-08-14 2003-09-24 スミスクライン・ビーチャム・コーポレイション カテプシンｋの阻害方法
CO5150165A1 (es) 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
DE69939752D1 (de) * 1998-12-23 2008-11-27 Smithkline Beecham Corp 4-Amino-azepan-3-on-Derivate als Protease-Inhibitors
CO5180541A1 (es) 1998-12-23 2002-07-30 Smithkline Beechman Corp Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
US20030044399A1 (en) 1998-12-23 2003-03-06 Smithkline Beecham Corporation Method of treatment
EP1175405A4 (en) * 1999-02-09 2002-05-15 Bristol Myers Squibb Co LACTAM INHIBITORS OF FACTOR Xa AND ASSOCIATED METHOD
DZ3083A1 (fr) 1999-02-19 2004-06-02 Smithkline Beecham Corp Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
UY26026A1 (es) 1999-03-16 2000-10-31 Smithkline Beecham Corportion Inhibidores de proteasas
UY26088A1 (es) 1999-03-31 2000-10-31 Smithkline Beecham Corp Inhibidores de proteasas
CZ2002323A3 (cs) 1999-07-28 2002-05-15 Aventis Pharmaceuticals Products Inc. Substituované oxoazaheterocyklylové sloučeniny a farmaceutické prostředky, které je obsahují
AU1474701A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
EP1231921A4 (en) 1999-11-10 2004-06-23 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034159A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034154A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
EP1231923A4 (en) 1999-11-10 2003-05-14 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034155A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
AU1474801A (en) * 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
WO2001034565A2 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034160A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
EP1229911A4 (en) 1999-11-10 2003-05-07 Smithkline Beecham Corp PROTEASE INHIBITORS
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
MXPA02009305A (es) * 2000-03-21 2003-03-12 Smithkline Beecham Corp Inhibidores de proteasa.
US20030114437A1 (en) 2002-10-17 2003-06-19 Cummings Maxwell D. Protease inhibitors
EP1320370A4 (en) 2000-09-01 2008-10-22 Smithkline Beecham Corp TREATMENT METHOD
JP2005513083A (ja) 2000-11-22 2005-05-12 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
US20040034013A1 (en) 2001-04-17 2004-02-19 Cummings Maxwell D Methods of treatment
US20040157828A1 (en) 2001-05-17 2004-08-12 Ren Xie Protease inhibitors
WO2003026770A1 (en) 2001-09-24 2003-04-03 Smithkline Beecham Corporation Method for removing metal from the products of olefin metathesis reactions
AU2002360409A1 (en) 2001-11-21 2003-06-10 Smithkline Beecham Corporation Methods and intermediates for the synthesis of azepines
WO2003099844A2 (en) 2002-05-22 2003-12-04 Smithkline Beecham Corporation Protease inhibitors
EP1511492A2 (en) 2002-05-22 2005-03-09 Smithkline Beecham Corporation Protease inhibitors
WO2003097593A2 (en) 2002-05-22 2003-11-27 Smithkline Beecham Corporation Protease inhibitors
US7109233B2 (en) 2002-05-22 2006-09-19 Smithkline Beecham Corporation Protease inhibitors
US7366462B2 (en) 2003-10-24 2008-04-29 Qualcomm Incorporated Method and apparatus for seamlessly switching reception between multimedia streams in a wireless communication system

Also Published As

Publication number Publication date
CZ20023168A3 (cs) 2003-02-12
EA005893B1 (ru) 2005-06-30
NO20024528D0 (no) 2002-09-20
NZ520588A (en) 2004-06-25
AR032877A1 (es) 2003-12-03
US7071184B2 (en) 2006-07-04
HUP0300068A2 (en) 2003-05-28
EA200201001A1 (ru) 2003-02-27
OA12323A (en) 2006-05-15
US7563784B2 (en) 2009-07-21
PE20011233A1 (es) 2002-02-07
AU4344101A (en) 2001-10-03
AP1540A (en) 2006-01-11
WO2001070232A1 (en) 2001-09-27
EP1307203A4 (en) 2005-08-17
BR0109356A (pt) 2003-06-03
CN1416346A (zh) 2003-05-07
PL357727A1 (en) 2004-07-26
US20060194787A1 (en) 2006-08-31
BG106962A (bg) 2003-03-31
SK13632002A3 (sk) 2003-02-04
AP2002002593A0 (en) 2002-09-30
AU2001243441B2 (en) 2004-11-25
UY26625A1 (es) 2001-09-28
MY141596A (en) 2010-05-31
DZ3318A1 (fr) 2001-09-27
MXPA02009305A (es) 2003-03-12
JP2003527429A (ja) 2003-09-16
CA2404206A1 (en) 2001-09-27
IL150964A0 (en) 2003-02-12
EP1307203A1 (en) 2003-05-07
KR20020082896A (ko) 2002-10-31
US20040044201A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
HUP0400202A3 (en) Imidazolidindion derivatives having metalloproteinase inhibitor effect, their use and pharmaceutical compositions containing them
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
HUP0300720A3 (en) Serine protease inhibitors, pharmaceutical compositions containing them and their use
KR100984939B9 (ko) 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
EE05020B1 (et) Glburiidi ravimkoostis
NO20025450L (no) Ny farmasöytisk sammensetning
ID30590A (id) Celana sekali pakai jenis-celana pendek
FI20011478A0 (fi) Farmaseuttinen koostumus
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
HUP0400193A3 (en) Imidazolindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
PL370766A1 (en) Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
DE50113294D1 (de) Hochselektive inhibitoren des urokinase-plasminogenaktivators
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
NO20013853D0 (no) Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer
FI20022128A (fi) Farmaseuttinen koostumus
DE60144265D1 (de) Halbleiterbauelement und dessen herstelllung
NO20025786L (no) Protaseinhibitorer
NO20030156D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
NO20025005L (no) Proteaseinhibitorer
DK1263719T3 (da) N-deacetylthiocolchin-derivater og farmaceutiske sammensætninger indeholdende disse.
NO20013669D0 (no) Reverse hydroksamatinhibitorer av matriks metalloproteinaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application